+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Managing the patient with diabetes mellitus and heart failure: issues and considerations



Managing the patient with diabetes mellitus and heart failure: issues and considerations



American Journal of Medicine 116 Suppl 5a: 76s



Heart failure affects nearly 5 million Americans and is associated with high morbidity and mortality rates. It is now recognized that activation of multiple neurohormonal systems is intrinsic in the pathophysiology of heart failure. Patients with diabetes mellitus are at high risk for heart failure, and some of the complications of diabetes (e.g., insulin resistance) contribute to the development and progression of heart failure, partly because of their effects on neurohormonal systems. Pharmacologic intervention directed toward these systems (i.e., angiotensin-converting enzyme [ACE] inhibition, use of aldosterone antagonists, and beta-adrenergic blockade) has been shown to decrease the morbidity and mortality associated with heart failure. Despite this knowledge, ACE inhibitors, aldosterone antagonists, and beta-blockers are grossly underused, and deaths and hospitalizations due to heart failure have steadily increased. Guidelines for the management of heart failure recommend the use of ACE inhibitors and beta-blockers in patients with mild, moderate, or severe disease. Aldosterone antagonists are recommended in severe heart failure, and recent data also support their use in mild to moderate heart failure. Concerns about the increased incidence of hypoglycemia, worsening dyslipidemia, and decreased insulin sensitivity with beta-blocker use may be preventing physicians from prescribing these agents for patients with diabetes with heart failure. Although evidence from earlier clinical trials justifies some of these concerns, newer vasodilating beta-blockers (e.g., carvedilol) have been shown to have a neutral or positive effect on dyslipidemia and insulin resistance. beta-Blockade in conjunction with ACE inhibition should be standard therapy for all patients with diabetes who have heart failure. Furthermore, early in-hospital initiation of neurohormonal intervention can provide earlier benefit to these patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012285471

Download citation: RISBibTeXText

PMID: 15019865

DOI: 10.1016/j.amjmed.2003.10.022


Related references

The patient with diabetes mellitus and heart failure: at-risk issues. American Journal of Medicine 115 Suppl 8a: 107s-110s, 2003

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation. Heart Failure 9(1):, 2016

Heart failure in diabetes mellitus: causal and treatment considerations. Minerva Cardioangiologica 52(6): 491-503, 2004

Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus. Results of the REMBO "rational effective multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure" study. Kardiologiia 48(9): 17-27, 2008

Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiology Clinics 22(4): 553-568, 2004

Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure". Kardiologiia 48(3): 58-68, 2008

Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation 133(24): 2459-2502, 2016

Prevalent diabetes mellitus in patients with heart failure and disease determinants in sub-Saharan Africans having diabetes with heart failure: a protocol for a systematic review and meta-analysis. Bmj Open 6(2): E010097, 2016

Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. American Heart Journal 182: 9-20, 2016

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Journal of Cachexia Sarcopenia and Muscle 1(2): 187-194, 2010

Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement. American Journal of Cardiology 110(9 Suppl): 50b, 2012

Antidiabetic medications in patients with heart failure. Minerva Endocrinologica 42(1): 53-63, 2017

Importance of cultural issues in managing a patient with diabetes. Consultant Pharmacist 22(5): 431-437, 2007

Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. American Heart Journal 146(5): 848-853, 2003

Acute heart failure in a patient with metabolic syndrome and diabetes mellitus: clinical evidence for direct positive influence of antidiabetic therapy on left ventricular function. Congestive Heart Failure 15(3): 148-150, 2009